Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

3.790 +0.060 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,218,491
Open 3.700
Bid (Size) 3.790 (30)
Ask (Size) 3.800 (4)
Prev. Close 3.730
Today's Range 3.660 - 3.830
52wk Range 3.095 - 6.630
Shares Outstanding 226,046,108
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
From ImmunoGen, Inc.
Via Business Wire
Why Shares of MacroGenics Jumped Thursday
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy. 
Via The Motley Fool

Performance

YTD
-20.55%
-20.55%
1 Month
-4.53%
-4.53%
3 Month
-16.70%
-16.70%
6 Month
-15.40%
-15.40%
1 Year
-11.03%
-11.03%

More News

Read More
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Earnings Scheduled For March 1, 2023
Via Benzinga
Analyst Ratings for Immunogen
Via Benzinga
Analyst Ratings for Immunogen
Via Benzinga
6 Analysts Have This to Say About Immunogen
Via Benzinga
What 6 Analyst Ratings Have To Say About Immunogen
Via Benzinga
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
Via Benzinga
ImmunoGen Reports Recent Progress and 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
From ImmunoGen, Inc.
Via Business Wire
What You Missed On Wall Street On Friday
Via Talk Markets
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
Via Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
Via Benzinga
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime
Via Benzinga
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Via Talk Markets
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
From ImmunoGen, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.